This section of the site is intended for members of the media and contains
information provided by biolitec pharma in the UK.
|
12/04/2004 |
Cancer Diagnosis and Therapy
mTHPC-mediated photodynamic therapy for early oral squamous cell carcinoma
>>more |
|
16/03/2004 |
"Fotodynamische therapie bij kanker lijkt
succesvol "
Video about Photodynamic therapy on dutch "Network TV"
>>more |
|
22/01/2004 |
Foscan Pivitol Study Abstract Published
The Foscan pivitol study abstract was published on the internet with the
full article to follow in Head & Neck in the near future.
>>more |
|
27/01/2003 |
Biolitec AG signs exclusive distribution agreements
for Foscan® in Eastern and Mediterranean countries – Additional mid-term
sales expectancy amounts to ca. EUR 14 mil.
>>more |
|
23/12/2002 |
BBC NEWS reports about treatment of head and neck
cancer with the biolitec pharmaceutical Foscan®
>>more |
|
02/12/2002 |
Biolitec AG will finalized integration of biolitec pharma Ltd., Scotland
within short time – launch of Foscan® started successfully with first sales
Turnover of first quarter 2002/2003 by Euro 4.5 million on same level as
previous year – Integration of biolitec pharma will be finalized in 2nd
quarter – promising start with head and neck cancer therapeutic
pharmaceutical Foscan® >>more |
|
09/30/2002 |
biolitec expects approx. EUR 100 million sales potential of approved
cancer drug
Foscan® is approved in Europe for the treatment of palliative head and neck
cancer – every year approx. >>more |
|
05/20/2002 |
Foscan® Data Presented at ASCO
Dr. Merrill Biel presented Foscan data at the annual ASCO conference in
Orlando, Florida, which concluded that Foscan® provides a therapeutic option
of significant benefit to patients with advanced head and neck cancer who
have exhausted all standard treatment options.
>>more |
